Large-scale Analysis Finds GLP-1 Agents Do Not Increase Risk of Pancreatic Cancer: New Study
Concerns have been raised that the use of glucagon-like peptide-1 receptor agonists (GLP-1) may increase the incidence of pancreatitis or pancreatic cancer, but a large-scale cohort analysis found that this was unfounded. The results of a study on the risk association of pancreatic cancer with the use of GLP-1 agents conducted by Dr. Rachel Dankner … Read more